Pacientes percepciones de paciente...The Corporate Reputation of Pharma in 2013 / Pantientview

The pharma industry’s reputation is getting worse - at least, in the eyes of 800 patient groups - according to a new international survey by PatientView. 


 Of those which responded to questioning in November and December last year, 35.4% said that multinational pharma companies had either an ‘excellent’ or ‘good’ reputation in 2013. 


While this is about the same result as in 2012, it is well below 2011 when 41% of respondents gave that answer. 

 The survey defined corporate reputation as “the extent to which pharma companies are meeting the expectations of patients and patient groups” and, on that basis, pharma was ranked seventh out of eight healthcare industries in 2013. 

 The only group with a worse reputation is commercial health insurers - while retail pharmacists (the sector with the most favourable reputation), biotechs and generic manufacturers all fared better (see table).

The 33 companies in the survey were pharma’s biggest names and included AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, both Mercks, Pfizer, Roche, and Sanofi. 

Cuesta abajo en la rodada...

Lundbeck and Novartis both saw their positions in the rankings fall year-on-year but ViiV Healthcare - a joint venture between GlaxoSmithKline, Pfizer and Japan’s Shionogi - made its first appearance in the corporate reputation survey and has come straight in at number one, topping the list in five key areas.